semaglutide and delta 8 Long-term kidney outcomes of in obesity cardiovascular disease in the SELECT trial Real-world use of oral versus

It was developed by the pharmaceutical giant Eli Lilly, and it is unique because it mimics three hunger hormones (GLP, GIP, and glucagon), while similar drugs on the market target one or two

What are your options if Ozempic stops working

In January 2026, a higher dose of 7.2mg was approved by the MHRA for those who need additional support

Wegovy Dosage and Administration Wegovy is given as a once-weekly pen injection starting at 0.25mg over four weeks

Retatrutide: A Novel Triagonist for Metabolic Disorders and CMC Advancements Eli Lilly Retatrutide, a novel triagonist, exemplifies the potential of incretin-based therapies for obesity and type 2 diabetes by targeting multiple metabolic pathways